Vanessa Wolfeler, Global Head of Rare Blood Disorders
Vanessa is focused on accelerating and expanding the global availability of our hemophilia treatments, overseeing the global launch of our treatment for aTTP, and prepare the market for a set of promising therapies in development for patients with rare blood disorders.
- VP Global Commercial at Vertex Pharmaceutical, US
- VP Global Product Strategy Lead, Hemophilia & Von Willebrand at Shire, US
- Head of Marketing - Hematology, Immunology and Oncology Franchise at Baxalta, France
- Various leadership position in sales and marketing at a Local, European and Global level at AstraZeneca and GlaxoSmithkline
- PharmD, MS Toxicology, Universite Paris Sud (Paris XI)
- Master’s degree, Intelligence Marketing, HEC Paris